Evidence map›Paper›PMID 33822811›Full record

ArticlePloS one2021

Tim-3 is dispensable for allergic inflammation and respiratory tolerance in experimental asthma.

Carolin Boehne, Ann-Kathrin Behrendt, Almut Meyer-Bahlburg, Martin Boettcher, Sebastian Drube, Thomas Kamradt, Gesine Hansen

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The Putative Role ofInternational journal of molecular sciences · 2024
    Article
  3. TIM-3-driven macrophage polarisation is associated to recalcitrant chronic rhinosinusitis with nasal polyps.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2024
    Article
  4. CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.Clinical reviews in allergy & immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carolin BoehneDepartment of Pediatrics and Adolescent Medicine, Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Lower Saxony, Germany.ORCID 0000-0003-1879-3347
Ann-Kathrin BehrendtDepartment of Pediatrics and Adolescent Medicine, Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Lower Saxony, Germany.
Almut Meyer-BahlburgDepartment of Pediatrics and Adolescent Medicine, Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Lower Saxony, Germany.
Martin BoettcherInstitute of Immunology, University Hospital Jena, Jena, Thuringia, Germany.ORCID 0000-0003-2911-8830
Sebastian DrubeInstitute of Immunology, University Hospital Jena, Jena, Thuringia, Germany.
Thomas KamradtInstitute of Immunology, University Hospital Jena, Jena, Thuringia, Germany.
Gesine HansenDepartment of Pediatrics and Adolescent Medicine, Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Lower Saxony, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3) has been described as a transmembrane protein, expressed on the surface of various T cells as well as different cells of innate immunity. It has since been associated with Th1 mediated autoimmune diseases and transplantation tolerance studies, thereby indicating a possible role of this receptor in counter-regulation of Th2 immune responses. In the present study we therefore directly examined the role of Tim-3 in allergic inflammation and respiratory tolerance. First, Tim-3-/- mice and wild type controls were immunized and challenged with the model allergen ovalbumin (OVA) to induce an asthma-like phenotype. Analysis of cell numbers and distribution in the bronchoalveolar lavage (BAL) fluid as well as lung histology in H&E stained lung sections demonstrated a comparable degree of eosinophilic inflammation in both mouse strains. Th2 cytokine production in restimulated cell culture supernatants and serum IgE and IgG levels were equally increased in both genotypes. In addition, cell proliferation and the distribution of different T cell subsets were comparable. Moreover, analysis of both mouse strains in our respiratory tolerance model, where mucosal application of the model allergen before immunization, prevents the development of an asthma-like phenotype, revealed no differences in any of the parameters mentioned above. The current study demonstrates that Tim-3 is dispensable not only for the development of allergic inflammation but also for induction of respiratory tolerance in mice in an OVA-based model.

Indexed as

AllergensAnimalsAsthmaCytokinesFemaleHepatitis A Virus Cellular Receptor 2Immune ToleranceImmunizationImmunoglobulin EInflammationMiceMice, Inbred BALB CMice, KnockoutOvalbuminRespiratory Tract DiseasesTh2 CellsAllergensCytokinesHavcr2 protein, mouseHepatitis A Virus Cellular Receptor 2Immunoglobulin EOvalbumin

Identifiers

PMID33822811
PMCPMC8023500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.